Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1-Reference-Cited by-同舟云学术

Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1

Published:2017-06-14 Issue:1 Volume:7 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Alshaker Heba,Wang Qi,Böhler Torsten,Mills Robert,Winkler Mathias,Arafat Tawfiq,Kawano Yoshiaki,Pchejetski Dmitri

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://www.nature.com/articles/s41598-017-03728-3.pdf

Reference34 articles.

1. van Oosterom, A. T., Schrijvers, D. & Schriivers, D. Docetaxel (Taxotere), a review of preclinical and clinical experience. Part II: Clinical experience. Anti-cancer drugs 6, 356–368 (1995).

2. Khan, M. A., Carducci, M. & Partin, A. W. The evolving role of docetaxel in the management of androgen independent prostate cancer. The Journal of urology 170, 1709–1716, doi: 10.1097/01.ju.0000088787.95124.4b (2003).

3. Hwang, C. Overcoming docetaxel resistance in prostate cancer: a perspective review. Therapeutic advances in medical oncology 4, 329–340, doi: 10.1177/1758834012449685 (2012).

4. Madan, R. A., Pal, S. K., Sartor, O. & Dahut, W. L. Overcoming chemotherapy resistance in prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 17, 3892–3902, doi: 10.1158/1078-0432.ccr-10-2654 (2011).

5. Murray, S., Briasoulis, E., Linardou, H., Bafaloukos, D. & Papadimitriou, C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer treatment reviews 38, 890–903, doi: 10.1016/j.ctrv.2012.02.011 (2012).

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway;Molecular Oncology;2024-08-02

2. Synergistic Action of Benzyl Isothiocyanate and Sorafenib in a Nanoparticle Delivery System for Enhanced Triple-Negative Breast Cancer Treatment;Cancers;2024-04-26

3. Prostate Cancer in Transplant Receivers—A Narrative Review on Oncological Outcomes;Biomedicines;2023-10-31

4. Canonical and novel strategies to delay or reverse aging;Molecular, Cellular, and Metabolic Fundamentals of Human Aging;2023

5. SOX2OT lncRNA Inhibition Suppresses the Stemness Characteristics of Esophageal Tumorspheres;Non-Coding RNA;2022-11-28